GWM
AQST icon

Geneos Wealth Management’s Aquestive Therapeutics AQST Stock Holding History

Geneos Wealth Management’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-23,300
Closed -$94K – 2854
2021
Q1 		$94K Buy
+23,300
New +$124K ﹤0.01% 1334

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BCL
Bracebridge Capital LLC Boston, Massachusetts $3.73B AUM 33.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
LI
Latash Investments Anchorage, Alaska $129M AUM 14.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CCM
CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return

Geneos Wealth Management's AQST Position: Q2 2021 in Review

Geneos Wealth Management sold out of Aquestive Therapeutics (AQST) in Q2 2021, closing a stake of 23,300 shares — an estimated $94K sold.

Geneos Wealth Management first reported a position in AQST in Q1 2021 and held it in 1 quarter. The position peaked at $94K in Q1 2021. 60 funds tracked by Wall St. Rank hold AQST as of Q2 2021.

  • Geneos Wealth Management reported no remaining Aquestive Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Geneos Wealth Management sold 23,300 Aquestive Therapeutics shares in Q2 2021, an estimated $94K.
  • Geneos Wealth Management first reported a position in Aquestive Therapeutics in Q1 2021 and held it in 1 quarter.
  • Geneos Wealth Management's Aquestive Therapeutics position peaked at $94K in Q1 2021.
  • 60 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2021.

Based on Geneos Wealth Management's 13F filing for Q2 2021, filed 8 Jul 2021.